# A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

> **NCT02586857** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 24 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** ACP-196

## Key facts

- **NCT ID:** NCT02586857
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01-25
- **Primary completion:** 2020-06-26
- **Final completion:** 2026-04-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586857, "A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-08-10 from https://api.ai-analytics.org/clinical/NCT02586857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*